You might also like
Zoetis Inc. is a global leader in the animal health industry, specializing in the discovery, development, manufacture, and commercialization of a wide range of products and services for animal health . The company offers medicines, vaccines, diagnostic products and services, biodevices, genetic tests, and precision animal health solutions for both companion animals and livestock across eight core species, including dogs, cats, horses, cattle, swine, poultry, fish, and sheep . Zoetis operates through two geographic segments, the United States and International, and markets its products directly to veterinarians and livestock producers in about 45 countries, while also contracting with distributors in regions where it does not have a direct commercial presence .
- Parasiticides - Provides treatments to protect animals from parasites, ensuring their health and well-being.
- Vaccines - Develops and manufactures vaccines to prevent diseases in various animal species.
- Dermatology - Offers products for the treatment and management of skin conditions in animals.
- Other Pharmaceuticals - Includes a range of pharmaceutical products for various health conditions in animals.
- Anti-infectives - Supplies medications to treat infections in animals, promoting recovery and health.
- Animal Health Diagnostics - Delivers diagnostic products and services to detect and monitor animal health issues.
- Medicated Feed Additives - Produces additives for animal feed to enhance health and growth.
-
Given the anticipated entry of new competitors in the dermatology space, particularly those with products carrying boxed warnings, what specific strategies is Zoetis implementing to defend market share for Apoquel and Cytopoint, and how might these strategies affect your promotional activities?
-
With the growth of alternative channels like retail and home delivery contributing significantly to sales (alternative channels were up 34% year-on-year in Q3), how is Zoetis adapting its sales and marketing strategy to address the shift away from traditional veterinary clinic visits, and what impact do you expect this to have on your relationships with veterinarians?
-
Considering that price contributed 6% to your 14% operational revenue growth in Q3 and that you anticipate the recent tailwinds from higher inflation to normalize, how do you plan to sustain your revenue growth as price-driven gains potentially decrease?
-
The MFA divestiture is expected to impact your Q4 revenue growth by reflecting a reduction of U.S. and international sales; can you elaborate on the magnitude of this impact and discuss the strategies you have in place to mitigate any negative effects on your overall financial performance?
-
You mentioned that headwinds in China have had approximately a 1% unfavorable impact on growth this year; could you provide more details on the specific challenges you're facing in the Chinese market and how you plan to address them to normalize growth in 2025?
Competitors mentioned in the company's latest 10K filing.
- Boehringer Ingelheim Animal Health Inc. - The animal health division of Boehringer Ingelheim GmbH .
- Merck Animal Health - The animal health division of Merck & Co., Inc. .
- Elanco Animal Health .
- IDEXX Laboratories .
- Several new start-up companies working in the animal health area .
Recent developments and announcements about ZTS.
Corporate Leadership
- Ester Banque, currently Executive Vice President and President, U.S. Operations, will leave to pursue other opportunities. She will serve in an advisory capacity until early 2025 to ensure a smooth transition .
- Wafaa Mamilli, currently Executive Vice President, Chief Digital & Technology Officer and Group President for China, Brazil and Precision Animal Health, will leave in early 2025 to pursue an external opportunity .
- Jamie Brannan has been appointed to the newly created role of Executive Vice President and Chief Commercial Officer, overseeing all commercial markets globally .
- Jared Shriver has been promoted to President, U.S. Operations, effective immediately, and will report to Mr. Brannan .
- Keith Sarbaugh has been promoted to Executive Vice President and Chief Digital & Technology Officer, effective immediately .
Board Change
Jamie Brannan has been appointed to the newly created role of Chief Commercial Officer, effective immediately. He will oversee all commercial markets globally .
Leadership Change
Leaving:
Stepping Up: